LH

LabcorpNYSE · Health Care Services · Health Care

Previous close

361.39

Change

−6.77 / −1.84%

FinDog View

Bullish

52-Week Range ?

244.52 – 371.00

P/E (TTM) ?

29.9

Forward P/E ?

16.0

Based on consensus earnings for the next 12 months

Market Cap

$29.3B

+17.29%

S&P 500 −0.91% over same period

Volume / Avg Volume

774K / 872K

0.89× average

Latest earnings analysisFY2026 Q2Reported 2026-07-30

Labcorp Q2 2026: revenue up 5.8%, adjusted EPS up 14.9%, guidance raised

Labcorp grew second quarter revenue 5.8% to $3.73 billion and lifted adjusted EPS 14.9% to $4.99, beating the $4.92 consensus estimate, while raising full-year revenue and adjusted EPS guidance. Both operating segments expanded margins, and the company returned $412.5 million to shareholders through buybacks and dividends. Cash flow is the one soft spot: free cash flow fell to $313.9 million from $542.7 million a year ago.

Read the full analysis →

Revenue$3.73BYoY +5.80%

EPS (non-GAAP)$4.99Beatest. $4.92

Next-quarter revenue guidance$14.77B ±0.4%YoY +295.80%

Next-day move−2.01%

Price History

Closing price · USD1M 6M 1Y 5Y

Historical P/E

Close ÷ trailing four-quarter EPS · Period median 25.81M 6M 1Y 5Y

Recent Earnings

Click to read the FinDog analysis

Period	Reported	Revenue	EPS Actual / Est.	Next-Day Move	Analysis
FY2026 Q2 Quarter ended 2026-06	2026-07-30	$3.7B	4.99 / 4.92	−2.01%	Read analysis →
FY2026 Q1 Quarter ended 2026-03	2026-04-30	$3.5B	4.25 / 4.21	−0.37%	Pending
FY2025 Q4 Quarter ended 2025-12	2026-02-17	$14.0B	4.07 / 4.06	+0.76%	Pending
FY2025 Q3 Quarter ended 2025-09	2025-10-28	$3.6B	4.18 / 4.26	−4.45%	Pending
FY2025 Q2 Quarter ended 2025-06	2025-07-24	$3.5B	4.35 / —	−1.02%	Pending
FY2025 Q1 Quarter ended 2025-03	2025-04-29	$3.3B	3.84 / —	+0.25%	Pending

Next Earnings

Date and consensus from the earnings calendar; the analysis is generated automatically after the releaseEarnings Calendar →

Report date

2027-02-15

in 106 days · time TBD

Consensus EPS

$4.61

Last quarter EPS $4.99

Avg. next-day move over the last 6 reports

±1.5%

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data

Valuation

P/E is at percentile 58 of its 5-year rangeMid-range

5-year range 21.9 – 45.5 · Median 28.8

Last 4 quarters: $677M in buybacks + $237M in dividends, 3.12% of market cap combined

P/E (TTM)

29.9

P/B

3.5

P/S

2.1

Dividend Yield

1.35%

Earnings Reaction

Over the last 6 reports, the stock moved ±1.5% on average on the first trading day after, rising 2 times

Most recent −2.01%

Volatility & Correlation

1-year beta 0.36 · Correlation with S&P 500 0.19Low beta

Annualized volatility 24% vs. 13% for the S&P 500

Insider Trading

View all →

Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions

Buy 0 · $0.00MSell 4 · $3.2MNet selling $3.2M

08-17ANDERSON KERRII BDirectorSell$0.95M3,000 shares · Avg price 318.02
08-11Schechter Adam HPresident & CEOSell$1.5M4,669 shares · Avg price 320.37
08-04Summy Amy B.EVP, Chief Marketing OfficerSell$0.28M924 shares · Avg price 306.74
08-03Wilkinson Peter JSVP, Chief Accounting OfficerSell$0.44M1,420 shares · 2 trades · Avg price 309.23

Multi-Quarter Financial Trends

View all quarters →

Last 12 quarters · As reported by the company

Quarter	Revenue ($B)	YoY	Gross Margin	Operating Income ($B)	Net Income ($B)	Free Cash Flow ($B)	EPS
FY2026 Q3	3.81	+6.9%	29.1%	0.40	0.26	0.41	3.22
FY2026 Q2	3.73	+5.8%	29.8%	0.45	0.30	0.31	3.64
FY2026 Q1	3.54	+5.8%	28.7%	0.38	0.28	0.07	3.35
FY2025 Q4	3.52	+5.6%	28.2%	0.27	0.17	0.49	1.98
FY2025 Q3	3.56	+8.6%	28.8%	0.40	0.26	0.28	3.12
FY2025 Q2	3.53	+9.5%	29.7%	0.39	0.24	0.54	2.84
FY2025 Q1	3.35	+5.3%	28.3%	0.33	0.21	-0.11	2.52
FY2024 Q4	3.33	+9.8%	26.9%	0.22	0.14	0.67	1.72
FY2024 Q3	3.28	+7.4%	27.6%	0.25	0.17	0.16	2.00
FY2024 Q2	3.22	+6.2%	28.8%	0.29	0.21	0.43	2.43
FY2024 Q1	3.18	+4.6%	28.2%	0.32	0.23	-0.16	2.69
FY2023 Q4	3.03	+39.5%	27.1%	-0.12	-0.17	0.41	-1.85

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →

Ticker	Company	Market Cap	P/E	Revenue YoY	Gross Margin	1M	View
LH	Labcorp	$29.3B	29.9	+6.9%	29.1%	+17.29%	Bullish
LLY	Lilly (Eli)	$1.34T	50.2	+38.6%	83.9%	+22.51%	Bullish	Compare
JNJ	Johnson & Johnson	$666B	41.3	+5.9%	68.1%	+3.20%	Bullish	Compare
ABBV	AbbVie	$522B	81.4	+10.2%	74.7%	+12.73%	Bullish	Compare
UNH	UnitedHealth Group	$367B	23.0	+0.4%	88.1%	+10.87%	Bullish	Compare
MRK	Merck & Co.	$371B	117.2	+5.1%	73.5%	+2.90%	Neutral	Compare
TMO	Thermo Fisher Scientific	$258B	36.4	+9.1%	—	+3.25%	Neutral	Compare
AMGN	Amgen	$254B	28.5	+9.5%	72.0%	+10.56%	Bullish	Compare
GILD	Gilead Sciences	$213B	—	+6.8%	81.1%	+14.51%	Neutral	Compare

The View in One Line

Revenue up 5.8%, margin 29.8%, adjusted EPS 4.99 beat 4.92, full-year guidance raised; but cash is thin and cash flow lags profit.

Updated 2026-10-30

View History

09-17Neutral → Bullish
Revenue up 5.8%, gross margin 29.8%, adjusted EPS 4.99 beat 4.92, full-year revenue and EPS guidance both raised; but cash is only $140M, debt $5.86B, and cash flow lags profit.

Notable Institutional Holders

Citadel Advisors · Ken Griffin$9.9MReduced −50%
Bridgewater Associates · Ray Dalio$783,440Reduced −75%

As of 2026-06-30

ETFs holding it

XLV Health Care Select Sector SPDR Fund0.44%
RSP Invesco S&P 500 Equal Weight ETF0.26%
VTV Vanguard Value ETF0.11%
VOO Vanguard S&P 500 ETF0.05%
IVV iShares Core S&P 500 ETF0.05%
SPY SPDR S&P 500 ETF Trust0.04%
VTI Vanguard Total Stock Market ETF0.04%

Weights estimated at latest prices

Key Events

08-14Management Change
Labcorp Executive Change: Central Laboratories President Departs, Caveney Succeeds
Megan D. Bailey will resign as Executive Vice President and President of Central Laboratories and International on September 4, 2026, and Brian J. Caveney will become President of Biopharma Laboratory Services effective September 1.Source ↗
05-26Governance
Labcorp Annual Meeting Completes Director Elections and Executive Compensation Vote
Labcorp held its annual meeting on May 21, 2026, electing 11 directors, passing an advisory vote on executive compensation, and approving Deloitte as 2026 auditor.Source ↗

Key Financial Trends

Quarterly Revenue ($B)3.8

Gross Margin29.1%

Free Cash Flow ($B)0.4